VOTING FORM Ordinary General Meeting

FC	OR	AGAINST	ABSTAIN					
	Proposals forming the subject of the first resolution: Examination of the consolidated accounts as on 31 December 2024. Resolution 1.1.: Approval of the statutory annual accounts as on 31 December 2024.							
	Examination of the consolidated and statutory annual Auditor's report on the financial year ended 31 December 2024.							
	Examination of the company's consolidated and statutory annual report prepared by the Board of Directors on the financial year ended 31 December 2024.							
	<u>Votes on</u>	the agenda for the Ordinary	General Meeting					
	and wishes to submit the	e following votes (<u>see instructio</u>	on 2 below):					
	for the above-mentioned	bility to vote by correspondence I number of shares adequately ne notice convening the Genera	registered on the Registration					
	above-mentioned Com Bourgetlaan 42, 1130 E	shes to participate in the Ordin pany, which will take place Brussels (Haren), Belgium, on the provisions of article 7: ations.	at the registered office at Tuesday 27 May 2025 at 10					
	Owner of	ordinary shares in its registered office at Avenue	n public limited company du Bourget 42, 1130 Brussels					
	The undersigned (for private individuals: surname, first name, occupation and place of residence; for legal entities: company name, company type, registered office and identity and position of the representative(s) - <u>see instruction 1 below</u>)							
	The undersigned (for pr	ivate individuals: surname. first	name, occupation an					

1.

2.

3.

Resolution	1.2.: Approval of the	appropriation	of the result, i.e.:

	Resolution 1.2.: Approval of the appropriation of the result, i.e.:							
	Loss for the financial year Profit brought forward from Result to be appropriated Gross dividend on shares Transfer to legal reserve Profit to be carried forwar (*) Gross dividend per she € 0.217 per ordinary shares	- €71,806,326.50 + €464,937,475.69 = €393,131,149.19 - €17,547,835.20 - €0.00 = €375,583,313.99 to a dividend net of withholding tax of						
FC	DR	AGAINST	ABSTAIN					
4.	. Proposal forming the subject of the second resolution: Discharge to be given to the Directors for the performance of their duties during the financial year ended 31 December 2024.							
FC	DR	AGAINST	ABSTAIN					
5.	 Proposal forming the subject of the third resolution: Discharge to be given to the Statutory auditor for the performance of his duties during th financial year ended 31 December 2024. 							
FC	DR	AGAINST	ABSTAIN					
6.	6. Proposals forming the subject of the fourth resolution: Resolution 4.1.: Renewal of the mandate of BALTISSE BV, permanently represented by Mr. Filiep Balcaen, as non-executive director for a new term of three years ending after the Ordinary General Meeting of 2028.							
FC	NP.	AGAINST	ARSTAIN					

FOR	AGAINST	ABSTAIN

Resolution 4.2.: Renewal of the mandate of MOROXCO BV, permanently represented by Ms. Elisa Vlerick, as non-executive and independent director for a new term of three years ending after the Ordinary General Meeting of 2028.

FOR	AGAINST	ABSTAIN

Resolution 4.3.: Establishment that the mandate of IMRADA BV, permanently represented by Ms Ingrid Merckx, as non-executive and independent director, expires after the Ordinary General Meeting of 27 May 2025. Decision to proceed with her replacement.

FOR	AGAINST	ABSTAIN

Resolution 4.4.: The Board of Directors recommends appointing as non-executive and independent director, FOXFIN BV, permanently represented by Ms Barbara De Saedeleer, for a term of three years expiring after the Ordinary General Meeting of 2028.

Ms Barbara De Saedeleer holds a master's degree in commercial and financial sciences, from Vlekho Business School in Brussels.

Ms Barbara De Saedeleer started her career in Corporate Banking at Paribas Bank in 1994. From 2007, she was CFO of Omega Pharma and member of the Executive Committee. In 2017, she became Chief Investments and Operations Officer at Ghelamco until March 2021. Since then, she has worked as a finance & strategy expert at various companies. She is Chief Strategy Officer at Erudite. Health in Kortrijk.

Ms Barbara De Saedeleer is an independent director of Montea, Beaulieu International Group, Kolmont Holding and Orsi Academy BV. She is a member of the Investment Committee of WAD Capital. Through her directorships at Montea and Beaulieu, two companies that are highly committed to ESG, Ms Barbara De Saedeleer has gained indepth insights into ESG challenges and strategies.

In replacement of IMRADA BV, permanently represented by Ms Ingrid Merckx, appointment of FOXFIN BV, permanently represented by Ms Barbara De Saedeleer, as non-executive and independent director, for a term of three years expiring after the Ordinary General Meeting of 2028.

FOR	AGAINST	ABSTAIN

Resolution 4.5.: The Board of Directors recommends as non-executive and independent director, Ref.lex BV, permanently represented by Ms Astrid Rahn, for a term of three years expiring after the Ordinary General Meeting of 2028.

Ms Astrid Rahn was born in Germany and grew up in Belgium. After completing her master's degree in Commercial Sciences, she started in Finance at Procter & Gamble. Afterwards, she became a consultant at The Boston Consulting Group. Over the past 30 years, Ms Rahn has steadily built her finance career in a number of US and Asian Blue Chip companies (P&G, Newell-Rubbermaid, Doosan, Bridgestone) to her current position as CFO Bridgestone EMEA, where she has taken on responsibilities for all aspects in Finance, IT, Legal and M&A. To this was recently added the start-up and expansion of ESG reporting.

Appointment of Ref.lex BV, permanently represented by Ms Astrid Rahn, as non-executive and independent director for a term of three years expiring after the Ordinary General Meeting of 2028.

FOR	AGAINST	ABSTAIN

7. Proposals forming the subject of the fifth resolution:

Resolution 5.1.: Confirmation as independent director of MOROXCO BV, permanently represented by Ms. Elisa Vlerick, within the meaning of article 7:87 of the Companies and Associations Code. MOROXCO BV and Ms. Elisa Vlerick meet all criteria as stated in article 7:87 of the Companies and Associations Code (as further elaborated in the field of

functional,	family	and	financial	criteria	as	provided	by	principle	3.5.	of	the	Corporate
Governanc	e Code	202	0).									

FOR	AGAINST	ABSTAIN

Resolution 5.2.: Appointment as independent director of FOXFIN BV, permanently represented by Ms. Barbara De Saedeleer, within the meaning of article 7:87 of the Companies and Associations Code. FOXFIN BV and Ms. Barbara De Saedeleer meet all criteria as stated in article 7:87 of the Companies and Associations Code (as further elaborated in the field of functional, family and financial criteria as provided by principle 3.5. of the Corporate Governance Code 2020).

FOR	AGAINST	ABSTAIN

Resolution 5.3.: Appointment as independent director of Ref.lex BV, permanently represented by Ms. Astrid Rahn, within the meaning of article 7:87 of the Companies and Associations Code. Ref.lex BV and Ms. Astrid Rahn meet all criteria as stated in article 7:87 of the Companies and Associations Code (as further elaborated in the field of functional, family and financial criteria as provided by principle 3.5. of the Corporate Governance Code 2020).

FOR	AGAINST	ABSTAIN

8. <u>Proposal forming the subject of the sixth resolution</u>:

On the proposal of the Board of Directors, acting on the recommendation of the Audit & Sustainability Committee and on the recommendation of the Works Council, the Ordinary General Meeting appoints the auditor PwC Bedrijfsrevisoren BV, with registered office at 1831 Diegem, Culliganlaan 5, for the assignment of limited assurance on the company's sustainability information for a term of three years. In accordance with Article 3:60 §2 WVV, this company appoints Wouter Coppens BV, for the performance of the mandate, with permanent representative Wouter Coppens, company auditor. The mandate expires after the Ordinary General Meeting which must approve the sustainability information by 31 December 2026.

The Ordinary General Meeting confirms the assignment to PwC Bedrijfsrevisoren BV to also report on the sustainability information on 31 December 2024.

The remuneration for this assignment amounts to € 126,200 per year (plus VAT, expenses, IBR contribution and lump sum allowance for technology and compliance costs) subject to annual adjustments depending on the evolution of the consumer price index or as agreed between the parties.

FOR	AGAINST	ABSTAIN

9. Proposals forming the subject of the seventh resolution:

Examination of the remuneration report for financial year 2024, as referred to in the corporate governance statement.

Resolution 7.1.: Approval of the remuneration report 2024.

FOR	AGAINST	ABSTAIN

Resolution 7.2.: Fixing and approval of the Directors' emoluments for 2025, i.e.:

- A single fixed fee for Directors of € 15,000 per year and for the Chairman of the Board of Directors of € 30,000 per year;
- Fees for Directors of € 2,500 per meeting and for the Chairman of the Board of Directors of € 5,000 per meeting.

FOR	AGAINST	ABSTAIN

Resolution 7.3.: Fixing of the amount of fees for the members of the Audit & Sustainability Committee for 2025 at € 2,500 per meeting and for the Chairman of the Audit & Sustainability Committee at € 5,000 per meeting.

FOR	AGAINST	ABSTAIN

Resolution 7.4.: Fixing of the amount of fees for the members of the Remuneration & Nomination Committee for 2025 at € 2,500 per meeting and for the Chairman of the Remuneration & Nomination Committee at € 5,000 per meeting.

FOR	AGAINST	ABSTAIN

In respect of the provisions laid down under Article 7:91 of the Companies and Associations Code concerning variable remuneration for the members of the Management Committee and the need to spread variable remuneration payments over a three year period in case certain thresholds are passed, the Board of Directors states the following:

- The principle of a spread over a three year period of variable remuneration payment would be applicable to the Managing Director and CEO, Jan Vergote, representing Coral & Wallace BV, as well as all other members of the Management Committee. They would not stay below the 25% threshold;
- The Remuneration and Nomination Committee and the Board of Directors reviewed the situation and are of the opinion that, considering the cyclical nature of the business, it would remain in the best interest of the company to allow a deviation.

Taking the above into consideration and since the target variable remuneration bonus payout for the Managing Director and CEO, as well as the other members of the Management Committee, surpasses the 25% maximum threshold, the Board of Directors proposes to the Ordinary General Meeting to approve the said deviation from the principle of a spread over

three years and hence allow the full payment of the variable remuneration within a shorter period.

Resolution 7.5.: Approval of the deviation from the principle of a spread over three years and to allow, given the cyclical nature of the business, the full payment of the variable remuneration within a shorter period for the benefit of the Managing Director and CEO, Jan Vergote, representing Coral & Wallace BV, as well as for the benefit of all other members of the Management Committee.

FOR	AGAINST	ABSTAIN
10II		ADOTAIN

10. Proposal forming the subject of the eighth resolution:

New edition of the Recticel Group Stock Option Plan.

The Board of Directors intends to issue a new edition of the Recticel Group Stock Option Plan in 2025 within the framework of the authorized capital, as in previous years. It requests the approval of the Ordinary General Meeting for this, not because this would be required by law, but in accordance with the principles of corporate governance.

Resolution 8: The Ordinary General Meeting approves the Board of Directors to issue in 2025, if appropriate, a new edition of the Recticel Group Stock Option Plan for the benefit of the senior executives of the Recticel Group. If the Board of Directors so decides, this new edition will include the issuance of up to 450,000 subscription rights, with an exercise period of three to a maximum of nine years and an unavailability period of three years, and which will be granted free of charge to the beneficiaries. The issue price will be determined by the Board of Directors in accordance with the Companies and Associations Code.

FOR	AGAINST	ABSTAIN

11. Proposal forming the subject of the nineth resolution:

The Recticel Group Stock Option Plan of June 2024 (subscription rights plan June 2024) issued by the Board of Directors contains a clause 5.2. which allows the beneficiary to immediately exercise the subscription rights in the event of a change of control (i.e. a transfer, through one or more transactions, of more than fifty percent (50%) of the voting rights) or a public takeover bid, in as the case may be under the conditions determined by the Board of Directors.

Resolution 9: Following the issue by the Board of Directors of the Recticel Group Stock Option Plan June 2024 (subscription rights plan June 2024), approval in accordance with article 7:151 of the Companies and Associations Code of clause 5.2. in the aforementioned Recticel Group Stock Option Plan.

FOR	AGAINST	ABSTAIN

Name and surname:	
Function:	
Place and date:	
Signature:	

RELEVANT INSTRUCTIONS

- (1) In order to participate to the General Meeting, shareholders must present proof of their identity (identity card or passport) and representatives of legal entities must, in addition, provide proof of their power of representation (relevant legal company documents).
 - Copies of the relevant proof must be attached to this form.
 - The Company must receive the voting form **no later than 21 May 2025.** The signed voting form, together with the relevant proof, can be provided by all possible means to the bureau, including by sending a scanned copy or picture of the form via e-mail to companysecretary@recticel.com. In the absence of the form and relevant proof at the General Meeting, the voting form is made null and void.
- (2) A vote by correspondence is final.
 - The forms in which neither the voting method nor the abstention are stated are null and void. If shareholders exercise their right under the legal and statutory provisions to submit new motions for resolutions regarding the items on the agenda, the votes by correspondence submitted before the publication of the updated agenda remain valid for the unchanged agenda items included in the current form. Votes on agenda items for which new motions for resolutions have been submitted, shall be disregarded.
 - In this case, shareholders can vote by correspondence on these new motions for resolutions by using the updated voting by correspondence form that the Company shall make available. If shareholders exercise their right under the legal and statutory provisions to put new items on the agenda of the General Meeting, shareholders can vote by correspondence on these new agenda items by using the updated voting by correspondence form that the Company shall make available in that case. The votes included in the current form on existing and unchanged agenda items shall remain valid. If no vote is cast on the new agenda items, this is considered as abstention.